North America Cardiac Marker Testing Market (2026-2031)
The North America Cardiac Marker Testing Market was valued at $1449.2 Million in 2026 and projected to reach to $2398.8 Million by 2031, representing a compound annual growth rate of 10.6%. North America's cardiac marker testing market is positioned for sustained growth through 2031, driven by demographic shifts toward an aging population with higher cardiovascular disease incidence.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America Cardiac Marker Testing Market Trends and Insights
- In North America, the market is driven by rising cardiovascular disease prevalence, aging populations, and increased adoption of point-of-care testing technologies.
- North America's healthcare infrastructure and reimbursement policies strongly support the deployment of advanced cardiac diagnostic solutions across hospitals, clinics, and emergency departments. The forecast period through 2031 reflects North America's commitment to early cardiac event detection and risk stratification.
- In North America, key growth catalysts include technological innovations in high-sensitivity troponin assays, integration of artificial intelligence in diagnostic workflows, and expanding access to rapid testing platforms.
- North America's competitive market landscape features both established diagnostic manufacturers and emerging innovators, all competing to capture share in this high-value segment..
Key Market Statistics
- CAGR (2026-2031) 10.6% CAGR
- Market Size, 2026 ~USD 1449.2 Million
- Forecast, 2031 ~USD 2398.8 Million
- Geography North America
North America Cardiac Marker Testing Market Overview
Market Valuation Growth :
North America's cardiac marker testing market is valued at $1,449.2 million in 2026 and is projected to reach $2,398.8 million by 2031, representing a robust 10.6% CAGR over the forecast period.
Cardiovascular Disease Burden :
Rising prevalence of cardiovascular diseases across North America, coupled with an aging population, is driving increased demand for early detection and monitoring through cardiac marker testing solutions.
Point-of-Care Testing Adoption :
North American healthcare providers are increasingly adopting point-of-care testing technologies for cardiac markers, enabling faster diagnosis and improved patient outcomes in clinical and emergency settings.
Favorable Reimbursement Environment :
North America's advanced healthcare infrastructure and supportive reimbursement policies create a conducive environment for market expansion and innovation in cardiac marker testing technologies.
North America Cardiac Marker Testing Market Dynamics
- The region's sophisticated healthcare infrastructure, combined with strong reimbursement frameworks and rapid adoption of advanced diagnostic technologies, supports market expansion.
- Point-of-care testing solutions are gaining traction as healthcare providers seek faster, more efficient diagnostic capabilities. Key growth drivers include increased awareness of early cardiac event detection, integration of cardiac biomarkers into clinical protocols, and technological innovations in testing platforms.
- The market will benefit from ongoing investments in healthcare technology and the shift toward preventive cardiology.
- North America's regulatory environment and emphasis on quality healthcare delivery position it as a leading market for cardiac marker testing solutions globally..
Related Ecosystem
In Vitro Diagnostics
Medical Devices
Key Takeaways
- North America's cardiac marker testing market will grow from $1,449.2M (2026) to $2,398.8M (2031) at a 10.6% CAGR.
- In North America, high-sensitivity troponin assays and point-of-care testing drive market expansion and clinical adoption.
- North America's aging population and cardiovascular disease burden create sustained demand for rapid diagnostic solutions.
- North America's advanced healthcare infrastructure and favorable reimbursement environment support continued market growth through 2031.
Cardiac Marker Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | OTHER CARDIAC BIOMARKERS (Biomarker Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.3% from 2026 to 2031 |
| Largest Segment | SINGLEPLEX ASSAY (Assay Format) |
| Market Size Base Year (Billions) | ~USD 5.55 (2026) |
| Revenue Forecast (Billions) | ~USD 9.06 (2031) |
| Segments Covered | Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User |
North America Cardiac Marker Testing Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product
- Instruments
- Reagents & Kits
By Technology
- Clinical Chemistry
- Immunoassay
- Immunoassays
By Type
- Chemiluminescence
- Contract Testing Laboratories
- Elisa
- Hospital Laboratories
- Immunofluorescence
- Lateral Flow Immunoassay
- Reference Laboratories
By Indication
- Acute Coronary Syndrome
- Atherosclerosis
- Congestive Heart Failure
- Ischemia
- Myocardial Infarction
By Biomarker Type
- Brain Natriuretic Peptide
- Creatinine Kinase-Mb
- High-Sensitivity C-Reactive Protein
- Homocysteine
- Myoglobin
- Other Cardiac Biomarkers
- Troponin I & T
By Point Of Testing
- Lab Tests
- Poc Tests
By Assay Format
- Multiplex Assay
- Multiplex Assays
- Singleplex Assay
- Singleplex Assays
By End User
- Academic Institutes
- Laboratory Testing Facilities
- Point-Of-Care Testing
Target Audience
- In Vitro Diagnostics Manufacturers : IVD companies need North America-specific market data to develop product portfolios, optimize pricing strategies, and identify growth opportunities in cardiac marker testing segments.
- Healthcare System Administrators : Hospital networks and healthcare systems require market insights to evaluate cardiac testing technologies, assess procurement strategies, and plan diagnostic service expansion.
- Clinical Laboratory Directors : Laboratory professionals need detailed market information to benchmark testing volumes, evaluate new cardiac marker assays, and optimize laboratory operations in North America.
- Medical Device Investors : Investment firms and venture capitalists seek North America market data to identify promising cardiac diagnostics companies, assess market potential, and guide funding decisions.
- Healthcare Consultants & Strategists : Consulting firms advising healthcare organizations require regional market intelligence to develop strategic recommendations, competitive analyses, and market entry strategies for North America.
Key Companies in the North America Cardiac Marker Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABBOTT LABORATORIES | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software), |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| THERMO FISHER SCIENTIFIC | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BIO-RAD LABORATORIES | United States | Public Company | Life Science,Clinical Diagnostics, |
| BIOMéRIEUX SA | France | Public Company | Clinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| DIASORIN SPA | Italy | Public Company | Immunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory, |
| REVVITY | United States | Public Company | Diagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins), |
| QUIDEL CORPORATION | United States | Public Company | Labs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care, |
| GUANGZHOU WONDFO BIOTECH CO., LTD. | China | Public Company | Rapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform, |
ABBOTT LABORATORIES
Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.
THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.
BIO-RAD LABORATORIES
Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.
BIOMéRIEUX SA
bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.
DIASORIN SPA
DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.
TOSOH CORPORATION
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.
QUIDEL CORPORATION
Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.
GUANGZHOU WONDFO BIOTECH CO., LTD.
Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| US | USD 2161 Million |
| Canada | USD 37 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Obtain precise market valuations for North America ($1,449.2M in 2026) with detailed country-level breakdowns for US and Canada, enabling accurate business planning and investment decisions.
- Growth Driver Analysis : Understand the specific factors propelling North America's 10.6% CAGR, including aging demographics, cardiovascular disease prevalence, and point-of-care technology adoption trends unique to the region.
- Competitive Landscape Intelligence : Gain insights into North American market dynamics, reimbursement policies, and healthcare infrastructure advantages that shape competitive positioning and market opportunities.
- Technology Adoption Trends : Identify emerging point-of-care testing technologies and diagnostic innovations gaining traction in North American healthcare systems and clinical settings.
- Strategic Market Entry Planning : Leverage North America-specific data to develop targeted go-to-market strategies, identify key stakeholders, and assess market entry barriers in this high-value healthcare region.
Frequently asked questions
What is the projected size of North America's cardiac marker testing market by 2031?
North America's cardiac marker testing market is projected to reach $2,398.8 million by 2031, growing from $1,449.2 million in 2026.
What is the CAGR for North America's cardiac marker testing market?
North America's cardiac marker testing market is expected to grow at a compound annual growth rate (CAGR) of 10.6% between 2026 and 2031.
What are the primary drivers of growth in North America's cardiac marker testing market?
In North America, growth is driven by rising cardiovascular disease prevalence, an aging population, technological innovations in high-sensitivity assays, and increased adoption of point-of-care testing platforms.
Which cardiac marker tests are most widely used in North America?
In North America, high-sensitivity troponin assays dominate the market, alongside B-type natriuretic peptide (BNP) and myoglobin tests, particularly in emergency and acute care settings.
How does North America's market compare to global cardiac marker testing trends?
North America's 10.6% CAGR slightly exceeds the global average of 10.3%, reflecting the region's advanced healthcare infrastructure, higher disease burden, and strong reimbursement support.
RESEARCH METHODOLOGY
The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
|
COMPANY NAME |
DESIGNATION |
|
Abbott Laboratories (US) |
Sales Manager |
|
F. Hoffmann-La Roche AG (Switzerland) |
Product Manager |
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).
Key Stakeholders
- Product Manufacturers, Distributors, and Suppliers
- Diagnostic Laboratories and Point-of-care Testing Centers
- Research Laboratories and CROs
- Ambulatory Testing Centers
- Contract Testing Laboratories
- Academic Universities and Medical Research Centers
- Research & Development (R&D) Centers
Report Objectives
- To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
- To study the impact of AI on the market, along with the macroeconomic outlook for each region
Available customizations:
MarketsandMarkets offers the following customizations for this market report.
Country Information
- Additional country-level analysis of the cardiac marker testing market
Company profiles
- Additional five company profiles of players operating in the cardiac marker testing market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market
Get the Full Cardiac Marker Testing Market Report
Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.
- US Cardiac Marker Testing Market
- Canada Cardiac Marker Testing Market
- UK Cardiac Marker Testing Market
- Germany Cardiac Marker Testing Market
- France Cardiac Marker Testing Market
- Italy Cardiac Marker Testing Market
- Spain Cardiac Marker Testing Market
- China Cardiac Marker Testing Market
- Japan Cardiac Marker Testing Market
- India Cardiac Marker Testing Market
- Australia Cardiac Marker Testing Market
- South Korea Cardiac Marker Testing Market
- Brazil Cardiac Marker Testing Market
- Mexico Cardiac Marker Testing Market
- Rest Of Europe Cardiac Marker Testing Market
- Rest Of Asia Pacific Cardiac Marker Testing Market
- Rest Of Latin America Cardiac Marker Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report